Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy

MD Galsky, NM Hahn, J Rosenberg… - Journal of clinical …, 2011 - ascopubs.org
Purpose Cisplatin-based combination chemotherapy is considered standard first-line
treatment for patients with metastatic urothelial carcinoma. However, a large proportion of …

Radiation pneumonitis and pulmonary fibrosis in non–small-cell lung cancer: Pulmonary function, prediction, and prevention

V Mehta - International journal of radiation oncology* biology …, 2005 - Elsevier
Although radiotherapy improves locoregional control and survival in patients with non-small-
cell lung cancer, radiation pneumonitis is a common treatment-related toxicity. Many …

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the …

S Atagi, M Kawahara, A Yokoyama, H Okamoto… - The lancet …, 2012 - thelancet.com
Background It is unknown whether combined chemoradiotherapy improves overall survival
in elderly patients with locally advanced non-small-cell lung cancer (NSCLC). The aim of …

European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer

D De Ruysscher, C Faivre-Finn, U Nestle… - Journal of clinical …, 2010 - ascopubs.org
Purpose To derive recommendations for routine practice and clinical trials for techniques
used in high-dose, high-precision thoracic radiotherapy for lung cancer. Methods A literature …

[HTML][HTML] Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of …

A Auperin, C Le Pechoux, JP Pignon, C Koning… - Annals of oncology, 2006 - Elsevier
Background Despite several randomised trials comparing radiotherapy alone with
concomitant radio-chemotherapy in patients with locally advanced non-small cell lung …

Never too old? Age should not be a barrier to enrollment in cancer clinical trials

MS Aapro, CH Köhne, HJ Cohen, M Extermann - The oncologist, 2005 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the implications of age bias in clinical trials. Describe the effects of applying clinical trial …

Impact of age and comorbidity on non–small-cell lung cancer treatment in older veterans

S Wang, ML Wong, N Hamilton, JB Davoren… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Because comorbidity affects cancer treatment outcomes, guidelines recommend
considering comorbidity when making treatment decisions in older patients with lung cancer …

Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters

AJ Hope, PE Lindsay, I El Naqa, JR Alaly… - International Journal of …, 2006 - Elsevier
Purpose: To determine the clinical, dosimetric, and spatial parameters that correlate with
radiation pneumonitis. Methods and Materials: Patients treated with high-dose radiation for …

[HTML][HTML] Nondosimetric risk factors for radiation-induced lung toxicity

S Wang - Seminars in radiation oncology, 2015 - Elsevier
The decision to administer a radical course of radiotherapy (RT) is largely influenced by the
dose-volume metrics of the treatment plan, but what are the patient-related and other factors …

[HTML][HTML] Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

M Aapro, C Bernard-Marty, EGC Brain, G Batist… - Annals of …, 2011 - Elsevier
Background Comorbidities and risk factors likely to complicate treatment are common in
elderly cancer patients. Anthracyclines remain the cornerstone of first-line therapy for non …